Search

Your search keyword '"von Metzler, Ivana"' showing total 158 results
Start Over Author "von Metzler, Ivana"
158 results on '"von Metzler, Ivana"'

1. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

Author

Mai, Elias K., Bertsch, Uta, Pozek, Ema, Fenk, Roland, Besemer, Britta, Hanoun, Christine, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Leypoldt, Lisa B., Heilmeier, Bernhard, Huhn, Stefanie, Vogel, Sabine K., Hundemer, Michael, Scheid, Christof, Blau, Igor W., Luntz, Steffen, Weinhold, Niels, Tichy, Diana, Holderried, Tobias A.W., Trautmann-Grill, Karolin, Gezer, Deniz, Klaiber-Hakimi, Maika, Müller, Martin, Shumilov, Evgenii, Knauf, Wolfgang, Michel, Christian S., Geer, Thomas, Riesenberg, Hendrik, Lutz, Christoph, Raab, Marc S., Benner, Axel, Hoffmann, Martin, Weisel, Katja C., Salwender, Hans J., Goldschmidt, Hartmut, Ahlborn, Miriam, Behringer, Joachim, Bernhard, Helga, Besemer, Britta, Bittenbring, Jörg, Blau, Igor Wolfgang, Bolling, Claus, Boquoi, Amelie, Debatin, Daniel, Egerer, Gerlinde, Fenk, Roland, Ferstl, Barbara, Fronhoffs, Stefan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Görner, Martin, Graeven, Ullrich, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Hoffmann, Martin, Holderried, Tobias A.W., Hopfer, Olaf, Janjetovic, Snjezana, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Kraemer, Doris Maria, Kropff, Martin, La Rosée, Paul, Mahlberg, Rolf, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Michel, Christian, Müller, Martin, Pönisch, Wolfram, Reimer, Peter, Riechel, Claudia, Ringhoffer, Mark, Rummel, Mathias, Runde, Volker, Salwender, Hans Jürgen, Schaich, Markus, Scheid, Christoph, Schmidt-Hieber, Martin, Schöndube, Daniel, Schroers, Roland, Schütte, Hans-Joachim, Shumilov, Evgenii, Staib, Peter, Strumberg, Dirk, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Verbeek, Walter, Weide, Rudolf, Weidmann, Eckhart, Weisel, Katja, de Wit, Maike, Bernhardt, Christiane, Fietz, Thomas, Grassinger, Jochen, Köchling, Georg, Neise, Michael, Schmitt, Stefan, Steiniger, Heike, Tschechne, Barbara, Whitlock, Bettina, Zaiß, Matthias, and Ziske, Carsten

Published
2024
Full Text
View/download PDF

2. CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Author

Kriegsmann, Katharina, Ton, Gigi Nu Hoang Quy, Awwad, Mohamed H. S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Munder, Markus, Dürig, Jan, Blau, Igor W., Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja C., Salwender, Hans J., Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., and Hundemer, Michael

Published
2024
Full Text
View/download PDF

3. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Author

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, and Goldschmidt, Hartmut

Published
2024
Full Text
View/download PDF

4. Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients

Author

Enssle, Julius C., Campe, Julia, Moter, Alina, Voit, Isabel, Gessner, Alec, Yu, Weijia, Wolf, Sebastian, Steffen, Björn, Serve, Hubert, Bremm, Melanie, Huenecke, Sabine, Lohoff, Michael, Vehreschild, Maria, Rabenau, Holger F., Widera, Marek, Ciesek, Sandra, Oellerich, Thomas, Imkeller, Katharina, Rieger, Michael A., von Metzler, Ivana, and Ullrich, Evelyn

Published
2024
Full Text
View/download PDF

5. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

Author

Adrian, Nicole, Bernhard, Helga, Böck, Hans-Peter, Bolling, Claus, Dingeldein, Gerrit, Emde, Till-Oliver, Ferstl, Barbara, Fietz, Thomas, Fronhoffs, Stefan, Fuhrmann, Stephan, Fuxius, Stefan, Geer, Thomas, Görner, Martin, Guenther, Barbara, Hartmann, Frank, Heilmeier, Bernhard, Heinsch, Michael, Hoffmann, Martin, Holderried, Tobias A.W., Klein, Stefan, Klump, Martin, Knauf, Wolfgang, La Rosée, Paul, Lange, Elisabeth, Lindemann, Walter, Lopez, Roderico, Mayer, Frank, Nückel, Holger, Papesch, Eva, Procaccianti, Maria, Reichart, Alexander, Rummel, Mathias, Scheuer, Lars, Schmitt, Hans-Roland, Staib, Peter, Steiniger, Heike, Tischler, Hans-Joachim, Ulshöfer, Thomas, Verbeek, Walter, Wacker, Alexander, Zirpel, Iris, Mai, Elias K, Goldschmidt, Hartmut, Miah, Kaya, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Krzykalla, Julia, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor W, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Kunz, Christina, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M, Kunz, Christian, Hensel, Manfred, Benner, Axel, Seidel-Glätzer, Andrea, Weisel, Katja C, Raab, Marc S, and Salwender, Hans J

Published
2024
Full Text
View/download PDF

6. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Author

Asemissen, Anne M, Behringer, Joachim, Bernhard, Helga, Bernhardt, Christiane, Bertsch, Uta, Besemer, Britta, Blau, Igor W, Bolling, Claus, Debatin, Daniel, Dingeldein, Gerrit, Dürig, Jan, Fenk, Roland, Ferstl, Barbara, Fest, Claudia, Fronhoffs, Stefan, Fuhrmann, Stephan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Görner, Martin, Graeven, Ullrich, Grassinger, Jochen, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Held, Gerhard, Hoffmann, Martin, Holderried, Tobias A W, Hopfer, Olaf, Huhn, Stefanie, Immenschuh, Peter, Kaddu-Mulindwa, Dominic, Khandanpour, Cyrus, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Köchling, Georg, Koenigsmann, Michael, Kostrewa, Philippe, Kraemer, Doris Maria, Kremers, Stephan, Kriegsmann, Katharina, Kropff, Martin, La Rosée, Paul, Luntz, Steffen P, Mahlberg, Rolf, Mai, Elias K, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Müller, Martin, Munder, Markus, Neise, Michael, Nievergall, Eva, Nückel, Holger, Pönisch, Wolfram, Procaccianti, Maria, Raab, Marc S, Rafiyan, Mohammed R, Reimer, Peter, Riecke, Armin, Riesenberg, Hendrik, Rummel, Mathias, Runde, Volker, Salwender, Hans J, Schaich, Markus, Scheid, Christoph, Schmidt-Hieber, Martin, Schmitt, Stefan, Schöndube, Daniel, Schroers, Roland, Schwarzer, Andreas, Staib, Peter, Steiniger, Heike, Sturmberg, Dirk, Thomalla, Jörg, Tichy, Diana, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Trummer, Arne, Tschechne, Barbara, Verbeek, Walter, Weinhold, Niels, Weisel, Katja C, Whitlock, Bettina, de Wit, Maike, Zaiß, Matthias, Ziske, Carsten, and Scheid, Christof

Published
2022
Full Text
View/download PDF

7. Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

Author

Shoumariyeh, Khalid, Csernalabics, Benedikt, Salimi Alizei, Elahe, Reinscheid, Matthias, Giese, Sebastian, Ciminski, Kevin, Kochs, Georg, Schwemmle, Martin, Lang-Meli, Julia, Maas, Michelle, Roehlen, Natascha, Karl, Vivien, Graeser, Anne, Sogukpinar, Oezlem, von Metzler, Ivana, Grathwohl, Denise, Rasche, Leo, Hebart, Holger, Kull, Miriam, and Emmerich, Florian

Subjects
IMMUNOLOGIC memory, HUMORAL immunity, T cells, VACCINATION status, IMMUNODEFICIENCY
Abstract

Background: Multiple myeloma (MM) patients are at high risk of severe infections including COVID-19 due to an immune dysregulation affecting both innate and adaptive immune responses. However, our understanding of the immune responses to infection and vaccination in MM patients is limited. To gain more detailed insights into infection- and vaccine-elicited T cell immunity in MM, we studied the CD8+ T cell response on the single-epitope level in SARS-CoV-2 convalescent and mRNA-vaccinated MM patients. Methods: We compared peptide/MHC class I tetramer-enriched SARS-CoV-2-specific CD8+ T cells and antibody responses in MM patients (convalescent: n = 16, fully vaccinated: n = 5, vaccinated convalescent: n = 5) and healthy controls (HCs) (convalescent: n = 58, fully vaccinated: n = 7) either after infection with SARS-CoV-2 alone, complete mRNA vaccination or SARS-CoV-2 infection and single-shot mRNA vaccination (hybrid immunity). Results: MM patients have lower frequencies and a lower proportion of fully functional virus-specific CD8+ T cells compared to HCs, after both SARS-CoV-2 infection and vaccination. CD8+ T cell memory subset distribution in MM patients is skewed towards reduced frequencies of central memory (TCM) T cells and higher frequencies of effector memory 1 (TEM1) T cells. In contrast, the humoral immune response was comparable in both cohorts after viral clearance. Notably, CD8+ T cell frequencies as well as the humoral immune response were improved by a single dose of mRNA vaccine in convalescent MM patients. Conclusions: MM patients have relative immunological deficiencies in SARS-CoV-2 immunity but benefit from hybrid immunity. These findings underline the relevance of vaccinations in this vulnerable patient group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

Author

Mai, Elias K, primary, Goldschmid, Hartmut, additional, Miah, Kaya, additional, Bertsch, Uta, additional, Besemer, Britta, additional, Hänel, Mathias, additional, Krzykalla, Julia, additional, Fenk, Roland, additional, Schlenzka, Jana, additional, Munder, Markus, additional, Dürig, Jan, additional, Blau, Igor W, additional, Huhn, Stefanie, additional, Hose, Dirk, additional, Jauch, Anna, additional, Kunz, Christina, additional, Mann, Christoph, additional, Weinhold, Niels, additional, Scheid, Christof, additional, Schroers, Roland, additional, von Metzler, Ivana, additional, Schieferdecker, Aneta, additional, Thomalla, Jörg, additional, Reimer, Peter, additional, Mahlberg, Rolf, additional, Graeven, Ullrich, additional, Kremers, Stephan, additional, Martens, Uwe M, additional, Kunz, Christian, additional, Hensel, Manfred, additional, Benner, Axel, additional, Seidel-Glätzer, Andrea, additional, Weisel, Katja C, additional, Raab, Marc S, additional, Salwender, Hans J, additional, Adrian, Nicole, additional, Bernhard, Helga, additional, Böck, Hans-Peter, additional, Bolling, Claus, additional, Dingeldein, Gerrit, additional, Emde, Till-Oliver, additional, Ferstl, Barbara, additional, Fietz, Thomas, additional, Fronhoffs, Stefan, additional, Fuhrmann, Stephan, additional, Fuxius, Stefan, additional, Geer, Thomas, additional, Görner, Martin, additional, Guenther, Barbara, additional, Hartmann, Frank, additional, Heilmeier, Bernhard, additional, Heinsch, Michael, additional, Hoffmann, Martin, additional, Holderried, Tobias A.W., additional, Klein, Stefan, additional, Klump, Martin, additional, Knauf, Wolfgang, additional, La Rosée, Paul, additional, Lange, Elisabeth, additional, Lindemann, Walter, additional, Lopez, Roderico, additional, Mayer, Frank, additional, Nückel, Holger, additional, Papesch, Eva, additional, Procaccianti, Maria, additional, Reichart, Alexander, additional, Rummel, Mathias, additional, Scheuer, Lars, additional, Schmitt, Hans-Roland, additional, Staib, Peter, additional, Steiniger, Heike, additional, Tischler, Hans-Joachim, additional, Ulshöfer, Thomas, additional, Verbeek, Walter, additional, Wacker, Alexander, additional, and Zirpel, Iris, additional

Published
2024
Full Text
View/download PDF

12. Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Author

Baertsch, Marc-Andrea, Schlenzka, Jana, Hielscher, Thomas, Raab, Marc S., Sauer, Sandra, Merz, Maximilian, Mai, Elias Karl, Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan, Glass, Bertram, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, von Metzler, Ivana, Lindemann, Hans W., Scheid, Christof, Blau, Igor-Wolfgang, Salwender, Hans J., Noppeney, Richard, Besemer, Britta, Weisel, Katja C., and Goldschmidt, Hartmut

Published
2025
Full Text
View/download PDF

13. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma:data from five randomized, controlled, phase III trials in 3700 patients

Author

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, Goldschmidt, Hartmut, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, and Goldschmidt, Hartmut

Abstract

Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p < 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.

Published
2024

14. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Author

Mai, Elias K., primary, Hielscher, Thomas, additional, Bertsch, Uta, additional, Salwender, Hans J., additional, Zweegman, Sonja, additional, Raab, Marc S., additional, Munder, Markus, additional, Pantani, Lucia, additional, Mancuso, Katia, additional, Brossart, Peter, additional, Beksac, Meral, additional, Blau, Igor W., additional, Dürig, Jan, additional, Besemer, Britta, additional, Fenk, Roland, additional, Reimer, Peter, additional, van der Holt, Bronno, additional, Hänel, Mathias, additional, von Metzler, Ivana, additional, Graeven, Ullrich, additional, Müller-Tidow, Carsten, additional, Boccadoro, Mario, additional, Scheid, Christof, additional, Dimopoulos, Meletios A., additional, Hillengass, Jens, additional, Weisel, Katja C., additional, Cavo, Michele, additional, Sonneveld, Pieter, additional, and Goldschmidt, Hartmut, additional

Published
2023
Full Text
View/download PDF

15. Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients

Author

Enssle, Julius C., primary, Campe, Julia, additional, Moter, Alina, additional, Voit, Isabel, additional, Gessner, Alec, additional, Yu, Weijia, additional, Wolf, Sebastian, additional, Steffen, Björn, additional, Serve, Hubert, additional, Bremm, Melanie, additional, Huenecke, Sabine, additional, Lohoff, Michael, additional, Vehreschild, Maria, additional, Rabenau, Holger F., additional, Widera, Marek, additional, Ciesek, Sandra, additional, Oellerich, Thomas, additional, Imkeller, Katharina, additional, Rieger, Michael A., additional, von Metzler, Ivana, additional, and Ullrich, Evelyn, additional

Published
2023
Full Text
View/download PDF

17. PB2070: IMMUNE RESPONSES AFTER SARS-COV-2 MRNA-VACCINATION AND INFECTION AT SINGLE CELL RESOLUTION IN PATIENTS WITH MULTIPLE MYELOMA

Author

Enssle, Julius C., primary, Campe, Julia, additional, Moter, Alina, additional, Voit, Isabel, additional, Gessner, Alec, additional, Yu, Ika Weija, additional, Wolf, Sebastian, additional, Steffen, Björn, additional, Oellerich, Thomas, additional, Serve, Hubert, additional, Bremm, Melanie, additional, Huenecke, Sabine, additional, Lohoff, Michael, additional, Vehreschild, Maria, additional, Rabenau, Holger F, additional, Widera, Marek, additional, Ciesek, Sandra, additional, Rieger, Michael A, additional, Imkeller, Katharina, additional, von Metzler, Ivana, additional, and Ullrich, Evelyn, additional

Published
2023
Full Text
View/download PDF

18. CD8+CD28−regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Author

Kriegsmann, Katharina, Ton, Gigi Nu Hoang Quy, Awwad, Mohamed H. S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Munder, Markus, Dürig, Jan, Blau, Igor W., Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja C., Salwender, Hans J., Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., and Hundemer, Michael

Published
2024
Full Text
View/download PDF

21. Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

Author

Kriegsmann, Katharina, primary, Manta, Calin, additional, Schwab, Ricarda, additional, Mai, Elias K., additional, Raab, Marc S., additional, Salwender, Hans J., additional, Fenk, Roland, additional, Besemer, Britta, additional, Dürig, Jan, additional, Schroers, Roland, additional, von Metzler, Ivana, additional, Hänel, Mathias, additional, Mann, Christoph, additional, Asemissen, Anne M., additional, Heilmeier, Bernhard, additional, Bertsch, Uta, additional, Huhn, Stefanie, additional, Müller-Tidow, Carsten, additional, Goldschmidt, Hartmut, additional, and Hundemer, Michael, additional

Published
2023
Full Text
View/download PDF

22. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Author

Goldschmidt, Hartmut, primary, Mai, Elias K, additional, Bertsch, Uta, additional, Fenk, Roland, additional, Nievergall, Eva, additional, Tichy, Diana, additional, Besemer, Britta, additional, Dürig, Jan, additional, Schroers, Roland, additional, von Metzler, Ivana, additional, Hänel, Mathias, additional, Mann, Christoph, additional, Asemissen, Anne M, additional, Heilmeier, Bernhard, additional, Weinhold, Niels, additional, Huhn, Stefanie, additional, Kriegsmann, Katharina, additional, Luntz, Steffen P, additional, Holderried, Tobias A W, additional, Trautmann-Grill, Karolin, additional, Gezer, Deniz, additional, Klaiber-Hakimi, Maika, additional, Müller, Martin, additional, Khandanpour, Cyrus, additional, Knauf, Wolfgang, additional, Scheid, Christof, additional, Munder, Markus, additional, Geer, Thomas, additional, Riesenberg, Hendrik, additional, Thomalla, Jörg, additional, Hoffmann, Martin, additional, Raab, Marc S, additional, Salwender, Hans J, additional, Weisel, Katja C, additional, Behringer, Joachim, additional, Bernhard, Helga, additional, Bernhardt, Christiane, additional, Blau, Igor W, additional, Bolling, Claus, additional, Debatin, Daniel, additional, Dingeldein, Gerrit, additional, Ferstl, Barbara, additional, Fest, Claudia, additional, Fronhoffs, Stefan, additional, Fuhrmann, Stephan, additional, Gaska, Tobias, additional, Goldschmidt, Hartmut, additional, Görner, Martin, additional, Graeven, Ullrich, additional, Grassinger, Jochen, additional, Heinsch, Michael, additional, Held, Gerhard, additional, Hopfer, Olaf, additional, Immenschuh, Peter, additional, Kaddu-Mulindwa, Dominic, additional, Klausmann, Martine, additional, Klein, Stefan, additional, Ko, Yon-Dschun, additional, Köchling, Georg, additional, Koenigsmann, Michael, additional, Kostrewa, Philippe, additional, Kraemer, Doris Maria, additional, Kremers, Stephan, additional, Kropff, Martin, additional, La Rosée, Paul, additional, Mahlberg, Rolf, additional, Martens, Uwe, additional, Neise, Michael, additional, Nückel, Holger, additional, Pönisch, Wolfram, additional, Procaccianti, Maria, additional, Rafiyan, Mohammed R, additional, Reimer, Peter, additional, Riecke, Armin, additional, Rummel, Mathias, additional, Runde, Volker, additional, Schaich, Markus, additional, Scheid, Christoph, additional, Schmidt-Hieber, Martin, additional, Schmitt, Stefan, additional, Schöndube, Daniel, additional, Schwarzer, Andreas, additional, Staib, Peter, additional, Steiniger, Heike, additional, Sturmberg, Dirk, additional, Tischler, Hans-Joachim, additional, Trummer, Arne, additional, Tschechne, Barbara, additional, Verbeek, Walter, additional, Whitlock, Bettina, additional, de Wit, Maike, additional, Zaiß, Matthias, additional, and Ziske, Carsten, additional

Published
2022
Full Text
View/download PDF

23. Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma

Author

Enssle, Julius C., Campe, Julia, Büchel, Sarah, Moter, Alina, See, Frederic, Grießbaum, Katharina, Rieger, Michael A., Wolf, Sebastian, Ballo, Olivier, Steffen, Björn, Serve, Hubert, Rabenau, Holger F., Widera, Marek, Bremm, Melanie, Huenecke, Sabine, Ciesek, Sandra, von Metzler, Ivana, and Ullrich, Evelyn

Published
2022
Full Text
View/download PDF

27. Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene

Author

Clees, Ada-Sophia, primary, Stolp, Verena, additional, Häupl, Björn, additional, Fuhrmann, Dominik C., additional, Wempe, Frank, additional, Seibert, Marcel, additional, Weber, Sarah, additional, Banning, Antje, additional, Tikkanen, Ritva, additional, Williams, Richard, additional, Brüne, Bernhard, additional, Serve, Hubert, additional, Schnütgen, Frank, additional, von Metzler, Ivana, additional, and Kurrle, Nina, additional

Published
2022
Full Text
View/download PDF

31. P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials

Author

Mai, Elias, primary, Hielscher, Thomas, additional, Bertsch, Uta, additional, Salwender, Hans J., additional, Munder, Markus, additional, Brossart, Peter, additional, Blau, Igor W., additional, Raab, Marc, additional, Duerig, Jan, additional, Giesen, Nicola, additional, Besemer, Britta, additional, Fenk, Roland, additional, Wattad, Mohammed, additional, Haenel, Mathias, additional, von Metzler, Ivana, additional, Graeven, Ullrich, additional, Scheid, Christoph, additional, Weisel, Katja, additional, and Goldschmidt, Hartmut, additional

Published
2021
Full Text
View/download PDF

32. Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Author

Ton, Gigi Nu Hoang Quy, Kriegsmann, Katharina, Awwad, Mohamed H.S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor Wolfgang, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Neubauer, Andreas, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe, Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja, Salwender, Hans, Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., and Hundemer, Michael

Published
2023
Full Text
View/download PDF

34. Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Author

Baertsch, Marc-Andrea, Schlenzka, Jana, Hielscher, Thomas, Raab, Marc S., Sauer, Sandra, Merz, Maximilian, Mai, Elias K., Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan, Glass, Bertram, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Hänel, Mathias, von Metzler, Ivana, Hans W., Lindemann, Scheid, Christof, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta, Weisel, Katja, and Goldschmidt, Hartmut

Published
2023
Full Text
View/download PDF

37. Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma : a multicohort analysis from phase III trials

Author

Mai, Elias, Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Brossart, Peter, Blau, Igor W., Raab, Marc, Dürig, Jan, Giesen, Nicola, Besemer, Britta, Fenk, Roland, Wattad, Mohammed, Haenel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Scheid, Christoph, Weisel, Katja, and Goldschmidt, Hartmut

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2021

39. Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up of the Phase III GMMG ReLApsE Trial

Author

Baertsch, Marc-Andrea, Schlenzka, Jana, Hielscher, Thomas, Raab, Marc S., Sauer, Sandra, Merz, Maximilian, Mai, Elias Karl, Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan, Glass, Bertram, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, von Metzler, Ivana, Lindemann, Hans W., Scheid, Christof, Blau, Igor-Wolfgang, Salwender, Hans J., Noppeney, Richard, Besemer, Britta, Weisel, Katja C., and Goldschmidt, Hartmut

Abstract

•No significant survival benefit with salvage autologous transplant versus lenalidomide/dexamethasone in relapsed and/or refractory myeloma•Time to progression after a frontline autologous transplant does not predict benefit from salvage autologous transplant

Published
2025
Full Text
View/download PDF

47. Enhancing the activation and releasing the brakes : a double hit strategy to improve NK cell cytotoxicity against multiple myeloma

Author

Tognarelli, Sara, Wirsching, Sebastian, von Metzler, Ivana, Rais, Bushra, Jacobs, Benedikt, Serve, Hubert, Bader, Peter, Ullrich, Evelyn, and Giuliani, Nicola

Subjects
Adult, Cytotoxicity, Immunologic, Interleukin-15, autologous stem cell transplantation, Immunology, Histocompatibility Antigens Class I, Hematopoietic Stem Cell Transplantation, adoptive cell therapy, NK cells, NKG2A blocking, Middle Aged, Lymphocyte Activation, Transplantation, Autologous, multiple myeloma, Killer Cells, Natural, Interferon-gamma, Medizinische Fakultät, checkpoint inhibition, Humans, Interleukin-2, ddc:610, NK Cell Lectin-Like Receptor Subfamily C, Original Research, Aged
Abstract

Natural killer (NK) cells are innate lymphocytes with a strong antitumor ability. In tumor patients, such as multiple myeloma (MM) patients, an elevated number of NK cells after stem cell transplantation (SCT) has been reported to be correlated with a higher overall survival rate. With the aim of improving NK cell use for adoptive cell therapy, we also addressed the cytotoxicity of patient-derived, cytokine-stimulated NK cells against MM cells at specific time points: at diagnosis and before and after autologous stem cell transplantation. Remarkably, after cytokine stimulation, the patients' NK cells did not significantly differ from those of healthy donors. In a small cohort of MM patients, we were able to isolate autologous tumor cells, and we could demonstrate that IL-2/15 stimulated autologous NK cells were able to significantly improve their killing capacity of autologous tumor cells. With the aim to further improve the NK cell killing capacity against MM cells, we investigated the potential use of NK specific check point inhibitors with focus on NKG2A because this inhibitory NK cell receptor was upregulated following ex vivo cytokine stimulation and MM cells showed HLA-E expression that could even be increased by exposure to IFN-γ. Importantly, blocking of NKG2A resulted in a significant increase in the NK cell-mediated lysis of different MM target cells. Finally, these results let suggest that combining cytokine induced NK cell activation and the specific check point inhibition of the NKG2A-mediated pathways can be an effective strategy to optimize NK cell therapeutic approaches for treatment of multiple myeloma.

Published
2018

49. Serum Levels of Total-RANKL in Multiple Myeloma

Author

Jakob, Christian Goerke, Andrea Terpos, Evangelos Sterz, Jan and Heider, Ulrike Kuehnhardt, Dagmar Ziefle, Susanne and Kleeberg, Lorenz Mieth, Maren von Metzler, Ivana Mueller, Christian Sezer, Orhan

Subjects
musculoskeletal diseases
Abstract

Background: Receptor activator of nuclear factor-kappa B ligand (RANKL) plays a key role in osteoclast activation in myeloma bone disease. The increased expression of RANKL in the bone marrow microenvironment was demonstrated in several studies, but there are only rare data on circulating RANKL levels in patients with multiple myeloma (MM). Patients and Methods: In the current study, we investigated the clinical significance of serum RANKL levels, using an enzyme-linked immunosorbent assay test that detects both free and osteoprotegerin (OPG)-bound RANKL (total-RANKL, tRANKL) in patients with newly diagnosed MM (n = 93) and monoclonal gammopathy of undetermined significance (MGUS; n = 20) compared with healthy controls (n = 20). Results: Circulating serum tRANKL was significantly elevated in patients with MM compared with controls (P < .001) or MGUS (P < .001). Furthermore, tRANKL levels were higher in smoldering MM versus MGUS (P = .031) and in symptomatic versus smoldering MM (P < .001). Serum tRANKL increased parallel to International Staging System stages I to III (P = .004) and correlated with the presence of lytic bone lesions (P < .001). Total-RANKL was a prognostic factor for overall survival in symptomatic MM (P = .043). A significantly longer progression-free survival was observed in patients with a > 50% decrease in tRANKL levels after 3 months of combined chemotherapy and bisphosphonate treatment. Conclusion: Our study demonstrates for the first time that serum tRANKL reflects advanced disease, lytic bone destruction, and poor prognosis in MM.

Published
2009

50. Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma

Author

Straka, Christian, primary, Schaefer-Eckart, Kerstin, additional, Bassermann, Florian, additional, Timon, Hansen, additional, Hertenstein, Bernd, additional, Langer, Christian, additional, Salwender, Hans, additional, Knop, Stefan, additional, Engelhardt, Monika, additional, Kropff, Martin, additional, Roesler, Wolf, additional, Decker, Thomas, additional, Hebart, Holger, additional, Frickhofen, Norbert, additional, Reichle, Albrecht, additional, Gerecke, Christian, additional, Metzner, Bernd, additional, Heidemann, Else, additional, Brummendorf, Tim H, additional, Ababei, Juliane, additional, Jung, Wolfram E, additional, Gramatzki, Martin, additional, Hentrich, Marcus, additional, Bojko, Peter, additional, von Metzler, Ivana, additional, Kaufmann, Martin, additional, Naumann, Ralph, additional, Kubin, Thomas, additional, Schmidt, Burkhard, additional, Walther, Jochem, additional, Dechow, Tobias, additional, Wandt, Hannes, additional, Schnabel, Brigitte, additional, Hinke, Axel, additional, and Einsele, Hermann, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results